XL888 Property

Boiling point:

695.1±55.0 °C(Predicted)

Density 

1.27±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

insoluble in H2O; insoluble in EtOH; ≥18.2 mg/mL in DMSO

form 

solid

pka

14.33±0.20(Predicted)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

XL888 Chemical Properties,Usage,Production

Uses

XL888, is a heat shock protein 90 (Hsp90) inhibitor. HSP90, is a chaperone that maintains the functionality of client proteins involved in cell proliferation, cell cycling, and apoptosis.1 XL888 is an ATP-competitive inhibitor of Hsp90.2 Through this action, specific client proteins are degraded, resulting in cell cycle arrest or apoptosis.3,4,5 XL888 is orally bioavailable and shows efficacy in tumor regression in gastric carcinoma and melanoma xenografts in mice

Biological Activity

xl-888 is a novel and orally-bioavailable inhibitor of heat shock protein 90 (hsp90) that selectively inhibits hsp90α and hsp90β with values of 50% inhibition concentration ic50 of 22 nm and 44 nm respectively. it also exerts considerably weaker inhibition against a range of other diverse kinases with ic50 more than 3600 nm for all. x-ray crystallographic analysis reveals that the xl-888 binds to hsp90 through the formation of h-bonding between the n-(r)-sec-butylanthranilamide moiety of xl-888 and asp93 of hsp90. in recent studies, xl-888 has exhibits strong anti-proliferative activities in a panel of tumor cells with values of ic50 ranging from 0.1 nm to 45.5 nm.paraiso kh, haarberg he, wood e, rebecca vw, chen ya, xiang y, ribas a, lo rs, weber js, sondak vk, john jk, sarnaik aa, koomen jm, smalley ks. the hsp90 inhibitor xl888 overcomes braf inhibitor resistance mediated through diverse mechanisms. clin cancer res. 2012; 18(9):2502-2514bussenius j, blazey cm, aay n, anand nk, arcalas a, baik t, bowles oj, buhr ca, costanzo s, curtis jk, defina sc, dubenko l, heuer ts, huang p, jaeger c, joshi a, kennedy ar, kim ai, lara k, lee j, li j, lougheed jc, ma s, malek s, manalo jc, martini jf, mcgrath g, nicoll m, nuss jm, pack m, peto cj, tsang th, wang l, womble sw, yakes m, zhang w, rice kd. discovery of xl888: a novel tropane-derived small molecule inhibitor of hsp90. bioorg med chem lett. 2012; 22(17): 5396-5404.

target

Hsp90